aTyr Pharma, Inc. (LIFE)
After hours:
| Previous close | 1.5900 |
| Open | 1.6100 |
| Bid | 1.5800 x 300 |
| Ask | 1.6100 x 200 |
| Day's range | 1.5400 - 1.6100 |
| 52-week range | 1.0800 - 2.7000 |
| Volume | |
| Avg. volume | 579,106 |
| Market cap | 108.705M |
| Beta (5Y monthly) | 1.23 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.9400 |
| Earnings date | 02 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 22.60 |
GlobeNewswireaTyr Pharma Announces First Quarter 2024 Results and Provides Corporate Update
Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected to complete enrollment in the second quarter of 2024. Ended the first quarter 2024 with $87.7 million in cash, cash equivalents, restricted cash and investments. SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today
Simply Wall St.aTyr Pharma Insiders Placed Bullish Bets Worth US$514.6k
It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it...
- GlobeNewswire
aTyr Pharma to Participate in April Investor Conferences
SAN DIEGO, April 01, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will participate in two upcoming investor conferences scheduled to take place in April 2024. Details of the conferences appear below: Conference: Evercore ISI Diamonds in the Rough Webinar DayDate: Thursday, April 4, 2024 Time: 10:3
